{
    "2021-10-09": [
        [
            {
                "time": "",
                "original_text": "错失新冠被抛售？复星出售亚能生物股份，可能还是要想‘资本局’ 减持股份数量",
                "features": {
                    "keywords": [
                        "复星",
                        "亚能生物",
                        "新冠",
                        "抛售",
                        "资本局",
                        "减持"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "赛诺菲退出mRNA新冠疫苗研究 沃森生物静待三期临床结果",
                "features": {
                    "keywords": [
                        "赛诺菲",
                        "mRNA",
                        "新冠疫苗",
                        "沃森生物",
                        "三期临床"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药",
                        "疫苗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "连卖4家子公司‘瘦身’ 大刀阔斧革新诊断业务 复星医药在下什么棋？",
                "features": {
                    "keywords": [
                        "复星医药",
                        "子公司",
                        "瘦身",
                        "革新",
                        "诊断业务"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "诊断"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "复星医药年内四次出售资产，将布局新赛道加速业务转型 资产异常",
                "features": {
                    "keywords": [
                        "复星医药",
                        "资产出售",
                        "新赛道",
                        "业务转型"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "资产配置"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}